Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.

Mok, Chi Chiu

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. [electronic resource] - Annals of the rheumatic diseases May 2011 - 778-84 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1468-2060

10.1136/ard.2010.143453 doi


Biomarkers--metabolism
Bone Density--drug effects
Bone Density Conservation Agents--adverse effects
Double-Blind Method
Drug Administration Schedule
Female
Glucocorticoids--administration & dosage
Hip Joint--physiopathology
Humans
Lipids--blood
Lumbar Vertebrae--physiopathology
Middle Aged
Osteoporosis, Postmenopausal--chemically induced
Prednisone--administration & dosage
Raloxifene Hydrochloride--adverse effects
Rheumatic Diseases--drug therapy